A review finds that bariatric surgery and GLP-1 drugs can improve both metabolic and mental health in some patients, but may also trigger mood episodes, self-harm, and depression in others — calling for psychiatric screening and monitoring.
Psychiatric screening neededBoth bariatric surgery and GLP-1 drugs can trigger mood episodes, self-harm, and altered drug metabolism — the review calls for mandatory psychiatric assessment before and monitoring after weight-loss treatments
What the researchers found
The review identifies a dual-edged relationship between weight-loss interventions and psychiatric outcomes:
Benefits: Both bariatric surgery and incretin-based therapies (GLP-1 receptor agonists) can improve metabolic health and, in some cases, mental well-being — likely through reduced inflammation, improved self-image, and metabolic normalization.
Risks: Post-bariatric surgery, studies show increased risks of mood episodes, self-harm behaviors, and altered metabolism of psychiatric medications (due to changes in gut absorption). For GLP-1 receptor agonists specifically, concerns have emerged about potential links to depression and suicidality, though the evidence is still being evaluated.
The authors recommend thorough psychiatric assessment before initiating any weight-loss intervention and long-term psychiatric monitoring after treatment.
Why it matters
As GLP-1 drugs are prescribed to millions of people for weight loss — many of whom have coexisting mood disorders — understanding the psychiatric implications is critical. The potential link between GLP-1 drugs and suicidality has generated regulatory attention (FDA, EMA reviews). This review provides the most comprehensive assessment of both the benefits and risks, advocating for a multidisciplinary approach that doesn't separate metabolic treatment from psychiatric care.
How the study worked
Narrative research review examining the published literature on the bidirectional relationship between mood disorders and obesity, with specific focus on psychiatric outcomes following metabolic bariatric surgery and weight-loss pharmacotherapy (particularly GLP-1 receptor agonists). The review synthesizes findings from observational studies, pharmacovigilance reports, and clinical trial data.
What this study cannot tell us
As a narrative review, this paper synthesizes but does not systematically quantify the evidence. The GLP-1/suicidality signal is based on pharmacovigilance reports and observational data, not controlled trials designed to assess psychiatric outcomes. The psychiatric risks of bariatric surgery may be confounded by pre-existing conditions, surgical stress, and lifestyle changes. The review does not quantify risk magnitudes or provide pooled estimates.
How to read the evidence
This is a narrative review synthesizing observational data, case reports, pharmacovigilance signals, and clinical trial secondary outcomes. While it provides a comprehensive overview of the bidirectional obesity-mood disorder relationship, the evidence for GLP-1/suicidality specifically remains preliminary and debated.
When this study was published
Published in 2025, this review is very current and addresses one of the most actively debated safety questions about GLP-1 drugs. The timing is relevant as regulatory agencies continue to evaluate the psychiatric safety profile of this drug class.
The bigger picture
The GLP-1 drug revolution is occurring alongside a global mental health crisis. Many patients seeking weight loss also have depression, anxiety, or bipolar disorder. This review highlights that the intersection of these conditions is poorly studied and that current clinical practice often treats them in silos. The call for integrated endocrinology-psychiatry care reflects a broader shift toward recognizing that metabolic and mental health are inseparable.
Questions still open
- Do specific GLP-1 receptor agonists carry different psychiatric risk profiles, or is this a class-wide concern?
- Could pre-treatment psychiatric screening identify patients who are at highest risk for mood deterioration with weight-loss interventions?
- How should psychiatric medication dosing be adjusted after bariatric surgery given altered gut absorption?
Common questions
Can GLP-1 drugs cause depression or suicidal thoughts?
Should people with depression avoid weight-loss treatments?
Read the original research
Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update.
Current obesity reports, 14(1), 82
Citation
Barbuti, Margherita; Weiss, Francesco; Perugi, Giulio. (2025). Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update.. Current obesity reports, 14(1), 82. https://doi.org/10.1007/s13679-025-00674-4